Loading clinical trials...
Loading clinical trials...
A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Chugoku, Japan
Chūbu, Japan
Kansai, Japan
Kantou, Japan
Start Date
May 1, 2009
Primary Completion Date
September 1, 2010
Completion Date
September 1, 2010
Last Updated
May 4, 2015
248
ACTUAL participants
ASP1585
DRUG
Lead Sponsor
Astellas Pharma Inc
NCT07241390
NCT06926660
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06717698